AEQUALIS™ FLEX REVIVE™ Study (REVIVE)

Rheumatoid Arthritis Clinical Trial

— REVIVE  

Official title:

AEQUALIS™ FLEX REVIVE™ Study (REVIVE)

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05500066
• Other study ID #: 20F-W-REVIVE-RM
• Status: Enrolling by invitation
• Start date: January 11, 2023
• Est. completion date: January 3, 2036

Study information

• Verified date: February 2024
• Source: Stryker Trauma GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available AEQUALIS FLEX REVIVE shoulder system in both the anatomic and reversed configurations.

The purpose of this study is to collect data needed to satisfy the European Union (EU) Medical Device Regulation (MDR) clinical post-market surveillance (PMS) and reporting requirements, and to support future regulatory submissions and peer-reviewed publications on device performance and safety.

Description:

This is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available AEQUALIS FLEX REVIVE shoulder system in both the anatomic and reversed configurations.

The primary outcome measure will be measured by the average improvement in American Shoulder and Elbow Surgeons (ASES) score from baseline to 24 months.

Secondary outcome measures include patient reported outcome measures (PROMs) and standard radiographic findings, including, but not limited to: device migration, component breakage, and bone characteristics.

Device revision and adverse events (AEs) will be assessed annually throughout the study. Range of motion and radiographic imaging assessments will also be performed at Years 1, 2, 5 and 10 post-operation.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 110
• Est. completion date: January 3, 2036
• Est. primary completion date: January 6, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older at the time of the informed consent.

• Informed and willing to sign an informed consent form approved by IRB or Ethics Committee (EC) (when applicable).

• Willing and able to comply with the requirements of the study protocol.

• Considered for a candidate for shoulder arthroplasty using the study device

• Meets indications for use requirements or other local, regional, or geographic specific regulatory requirements

Exclusion Criteria:

• Not able to comply with the study procedures based on the judgment of the assessor (e.g., cannot comprehend study questions, inability to keep scheduled assessment times)

• Patient belongs to a vulnerable group of patients, including minor patients, those unable to decide for themselves to participate or needing a Legally Authorized Representative (LAR), or others who could be subject to coercion (patients who may not be acting on their own initiative) (referred as "vulnerable subject" in the section 3.44 of the ISO 14155 norm).

• Active local or systemic infection, sepsis, or osteomyelitis

• Poor bone quality, where there could be considerable migration of the prothesis and/or a chance of fracture of the humerus or glenoid (reassessed at time of surgery)

• Significant injury to the brachial plexus

• Inadequate bone stock in the proximal humerus or glenoid fossa for supporting the components

• Neuromuscular disease (e.g., joint neuropathy)

• Patient with known allergy to one of the product materials

• Metabolic disorders which may impair bone formation

• Patient pregnancy

• Planned for two-stage surgery (reassessed at time of surgery)

Related Conditions & MeSH terms

• Arthritis
• Avascular Necrosis
• Correction of Functional Deformity
• Humeral Fractures
• Necrosis
• Osteoarthritis
• Osteoarthritis Shoulder
• Rheumatoid Arthritis
• Rotator Cuff Injuries
• Rotator Cuff Tears
• Traumatic Arthritis

Intervention

Device:
• Aequalis Flex Revive Shoulder System
The AEQUALIS FLEX REVIVE Shoulder System is intended for use as: A replacement of shoulder joints in primary anatomic or in primary reverse A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains. The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision.

Locations

Country	Name	City	State
United States	Coastal Orthopedics	Bradenton	Florida
United States	Western Orthopaedics, P.C.	Denver	Colorado
United States	Baptist Health Lexington	Lexington	Kentucky
United States	Foundation for Orthopaedic Research & Education	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Stryker Trauma GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average Improvement from Baseline to last follow-up visit in ASES Score	ASES Score = American Shoulder and Elbow Surgeons Score, 11 items with total score reported out of 100 measuring pain and activity of patient's evaluated shoulder where lower scores indicate more pain and less function	24 Month
Secondary	Constant Score	A score based on a 100-point scale determined by objective measurements made by the physician in the clinic and subjective values based on pain and activities of daily living reported by the patient.	through study completion, an average of 1 year
Secondary	SANE	Single question that asks the patient to rate their shoulder on a scale from 0 to 100, where 100 is normal.	through study completion, an average of 1 year
Secondary	EQ 5-D	Consists of a 5-question measure where patients rate their health today on a 5-point scale on a 5-dimension scale and a visual analogue scale to measure overall health status.	through study completion, an average of 1 year
Secondary	Patient Satisfaction	Single subjective question "How satisfied are you with your shoulder?"	through study completion, an average of 1 year
Secondary	Radiographic Findings	Images will be reviewed by a single orthopedic surgeon to assess for standard radiographic findings, including, but not limited to: device migration, component breakage, and bone characteristics.	Baseline, 1 year, 2 year, 5 year and 10 year